Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Blood (2019) 134 (Supplement_1): 1568.

https://doi.org/10.1182/blood-2019-123446

Published: 2019

Journal Articles

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

Blood (2019) 134 (Supplement_1): 2878.

https://doi.org/10.1182/blood-2019-130603

Published: 2019

Journal Articles

A Retrospective Analysis of Outcomes of Diffuse Large B Cell Lymphoma (DLBCL) in the Elder Patients in China

Peng Liu, Ying Han, Jianliang Yang, Xiaohui He, Changgong Zhang, Shengyu Zhou, Yan Qin, Liqiang Zhou, Song Yongwen, Ming-Zhe Han, MD, Yan Sun, Yuankai Shi, MD PhD

Blood (2018) 132 (Supplement 1): 5410.

https://doi.org/10.1182/blood-2018-99-116641

Published: 2018

Journal Articles

Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition

Douglas W. Blayney, MD, Ene Ette, PhD, Stephan Ogenstad, PhD, Yuankai Shi, MD PhD, Lihua Du, Kenneth Lloyd, PhD, Lan Huang, PhD, Ramon Mohanlal, PhD MD

Blood (2018) 132 (Supplement 1): 2068.

https://doi.org/10.1182/blood-2018-99-113569

Published: 2018

Journal Articles

A Prognostic Nomogram and Survival Analysis in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Shiyu Jiang, Yan Qin, Peng Liu, Jiangliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Lin Gui, Changgong Zhang, Liqiang Zhou, Ming-Zhe Han, Yan Sun, Yuankai Shi, MD PhD

Blood (2018) 132 (Supplement 1): 2994.

https://doi.org/10.1182/blood-2018-99-116442

Published: 2018

Journal Articles

Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Yuankai Shi, MD PhD, Mei Dong, MD, Jun Zhu, MD, Daobin Zhou, MD, Huiqiang Huang, MD, Ping Tu, MD, Weijing Zhang, MD, Xiaonan Hong, MD, Xielan Zhao, MD, Jianfang Sun, MD, Yuehua Liu, MD, Lugui Qiu, MD PhD, ZhiXiang Shen, MD, Jifeng Feng, MD, Xiaoyan Ke, MD PhD

Blood (2015) 126 (23): 1513.

https://doi.org/10.1182/blood.V126.23.1513.1513

Published: 2015

Journal Articles

Treatment Outcome and Prognostic Model for Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Retrospective Study in a Cohort of 305 Patients with Long Term Follow-up

Yuankai Shi, MD PhD, Bo Jia, Xiaohui He, MD, Youwu Shi, Mei Dong, MD, Jianliang Yang, MD, Liqiang Zhou, MD, Shengyu Zhou, MD, Peng Liu, MD, Yan Qin, MD, Sheng Yang, MD, Hua Lin, MD, Lin Gui, MD, Changgong Zhang, MD, Lin Wang, MD, Shanshan Chen, MD, Puyuan Xing, MD, Hongnan Mo, MD, Mingzhe Han, MD

Blood (2015) 126 (23): 2718.

https://doi.org/10.1182/blood.V126.23.2718.2718

Published: 2015

Journal Articles

Clinical Features and Prognosis of CD20-Positive Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) in Chinese Patients: A Retrospective Single Institution Analysis

Shaoxuan Hu, Xiaohui He, MD, Yuankai Shi, MD PhD, Sheng Yang, MD, Yan Qin, MD, Jianliang Yang, MD, Mei Dong, MD, Shengyu Zhou, MD, Peng Liu, MD, Lin Gui, MD, Changgong Zhang, MD, Liqiang Zhou, MD

Blood (2015) 126 (23): 5045.

https://doi.org/10.1182/blood.V126.23.5045.5045

Published: 2015

Journal Articles

Efficacy and Safety of Gemcitabine-Based Combination Regimens in Patients with Extranodal Natural Killer/T Cell Lymphoma, Nasal Type

Jingjing Wang, Mei Dong, MD, Xiaohui He, MD, Weihu Wang, MD, Peng Liu, MD, Jianliang Yang, MD, Yan Qin, MD, Lin Gui, MD, Sheng Yang, MD, Yexiong Li, MD PhD, Yuankai Shi, MD PhD, Lugui Qiu, MD

Blood (2014) 124 (21): 3071.

https://doi.org/10.1182/blood.V124.21.3071.3071

Published: 2014

Journal Articles

CRM1 As a New Therapeutic Target For Non-Hodgkin Lymphoma

Yuankai Shi, MD, PhD, Jianfei Wang, PhD, Xiaohong Han, PhD, Ningning Zhang, MD, Shuai Wang, PhD, Jiarui Yao

Blood (2013) 122 (21): 1300.

https://doi.org/10.1182/blood.V122.21.1300.1300

Published: 2013

Journal Articles

Safety and Clinical Activity Of Crizotinib In Patients With ALK -Rearranged Hematologic Malignancies

Carlo Gambacorti-Passerini, MD, Keizo Horibe, MD, PhD, Fadi Braiteh, MD, CPI, Hui-qiang Huang, MD, PhD, Yuankai Shi, MD, PhD, Matthew H Taylor, MD, Nicoletta Brega, Jolanda Paolini, Paulina Selaru, Tae Min Kim, MD, PhD

Blood (2013) 122 (21): 4342.

https://doi.org/10.1182/blood.V122.21.4342.4342

Published: 2013

Journal Articles

The Revised High-Dose Regimen of Beacop in the Primary Treatment of the Advanced Hodgkin's Lymphoma: A Interim Report

Peng LIU, Yuankai Shi, MD, PhD, Zhao Wang

Blood (2012) 120 (21): 4783.

https://doi.org/10.1182/blood.V120.21.4783.4783

Published: 2012

Journal Articles

A SCID-hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma.

Michael Wang, MD, Yuankai Shi, MD, PhD, Liang Zhang, PhD, Xiaohong Han, MD, Jing Yang, PhD, Jianfei Qian, PhD, Sungyoul Hong, PhD, Pei Lin, MD, Jorge Romaguera, MD, Larry W. Kwak, MD, PhD, Qing Yi, MD, PhD

Blood (2007) 110 (11): 2337.

https://doi.org/10.1182/blood.V110.11.2337.2337

Published: 2007

Journal Articles

Bortezomib Is Synergistic with Rituximab and Cyclophosphamide in Inducing Apoptosis of Mantle Cell Lymphoma Cells In Vitro and In Vivo.

Liang Zhang, PhD, Yuankai Shi, MD, PhD, Xiaohong Han, PhD, Jing Yang, PhD, Jianfei Qian, PhD, Larry W. Kwak, MD, PhD, Jorge Romaguera, MD, Qing Yi, MD, PhD, Michael Wang, MD

Blood (2007) 110 (11): 4514.

https://doi.org/10.1182/blood.V110.11.4514.4514

Published: 2007

NARROW

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 Diffuse Large B-Cell Lymphoma Study

A Retrospective Analysis of Outcomes of Diffuse Large B Cell Lymphoma (DLBCL) in the Elder Patients in China

Plinabulin, a Novel Small Molecule in Development for Chemotherapy-Induced-Neutropenia (CIN) Prevention, Mobilizes CD34+ Cells through a Mechanism of Action (MoA) Different from G-CSF and from CXCR4 Inhibition

A Prognostic Nomogram and Survival Analysis in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Treatment Outcome and Prognostic Model for Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Retrospective Study in a Cohort of 305 Patients with Long Term Follow-up

Clinical Features and Prognosis of CD20-Positive Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) in Chinese Patients: A Retrospective Single Institution Analysis

Efficacy and Safety of Gemcitabine-Based Combination Regimens in Patients with Extranodal Natural Killer/T Cell Lymphoma, Nasal Type

CRM1 As a New Therapeutic Target For Non-Hodgkin Lymphoma

Safety and Clinical Activity Of Crizotinib In Patients With ALK -Rearranged Hematologic Malignancies

The Revised High-Dose Regimen of Beacop in the Primary Treatment of the Advanced Hodgkin's Lymphoma: A Interim Report

A SCID-hu In Vivo Mouse Model of Human Primary Mantle Cell Lymphoma.

Bortezomib Is Synergistic with Rituximab and Cyclophosphamide in Inducing Apoptosis of Mantle Cell Lymphoma Cells In Vitro and In Vivo.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only